Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals

Marco Bongiovanni(Luigi Sacco Hospital), Antonella d’Arminio Monforte(University of Milan), Paola Cicconi(University of Oxford), Simona Landonio(ASST Fatebenefratelli Sacco), Federica Tordato(Humanitas University), Teresa Bini(Ospedale San Paolo), Elisabetta Chiesa(University of Milan), Paola Meraviglia(Luigi Sacco Hospital), Letizia Testa(Ospedale di Circolo di Busto Arsizio), Antonio Di Biagio

International Journal of Antimicrobial Agents

May 5, 2005

10.1016/j.ijantimicag.2005.03.003

Cited by 33

Related Papers

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

|The Lancet|2020|5k

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

|The Lancet|2003|1.2k

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

|The Lancet|2021|1.2k

Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study

|AIDS|2003|987